DHR vs NVDA: Which Is the Better Buy?

Side-by-side comparison of Danaher Corporation and NVIDIA Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Danaher Corporation Β· Healthcare
$177.17
+8.9% upside to fair value
Grade B High Quality
VS
NVIDIA Corporation Β· Technology
$210.69
+45.0% upside to fair value
Grade B High Quality
QuantHub Verdict
NVDA has more upside to fair value (+45.0%). NVDA trades at a lower forward P/E (32.1x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric DHR NVDA
Current Price $177.17 $210.69
Fair Value Estimate $192.90 $305.50
Upside to Fair Value +8.9% +45.0%
Market Cap $125.4B $5,103.1B
Forward P/E 34.1x 32.1x
EV / EBITDA 20.8x 26.5x
Price / Sales 5.1x 20.1x
Price / FCF 23.7x 42.9x
Revenue Growth YoY +3.7% +85.2%
Gross Margin 60.7% 74.1%
Operating Margin 21.0% 64.0%
Return on Equity 7.1% 111.7%
Dividend Yield 0% 0%
FCF Yield 4.22% 2.33%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
DHR β€” Danaher Corporation
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
NVDA β€” NVIDIA Corporation
NVIDIA Corporation is a leading technology company specializing in semiconductors, particularly GPUs and AI accelerators, with a dominant market position in AI training markets holding over 80% share. The company exhibits exceptional business quality with a founder-led management team boasting over 30 years of continuous leadership, very high profitability with gross margins above 74% and net mar…
Accumulation Zones
Metric DHR NVDA
Zone Low $144.68 $229.12
Zone High $163.97 $259.68
In Buy Zone? No Yes
← DHR Research    NVDA Research β†’    All Research